Item 2.02 Results of Operations and Financial Condition.
On
Because the Company's financial statements for the fourth quarter and fiscal
year ended
Item 7.01 Regulation FD Disclosure.
The information set forth in Item 2.02 of this Current Report is incorporated into this Item 7.01 by reference.
The information furnished in Item 2.02 and Item 7.01 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
Forward Looking Statements
Any statements contained in this Current Report on Form 8-K that do not describe
historical facts may constitute forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, including statements regarding
management's current expectations with respect to our fourth quarter 2022 and
full year 2022 performance, including our revenue growth, and statements
regarding our fiscal year 2023 financial outlook, including our outlook for
organic revenue growth. Any forward-looking statements contained herein are
based on current expectations, but are subject to risks and uncertainties that
could cause actual results to differ materially from those indicated, including,
but not limited to, risks and uncertainties relating to the preliminary nature
of the Company's fourth quarter 2022 and full year 2022 financial information,
which is subject to completion of the Company's year-end-audit, risks and
uncertainties relating to the length and severity of the COVID-19 pandemic, the
impact of the pandemic on global economic conditions, the impact of any supply
chain disruptions, continued volatility in the capital markets, effects from
inflation, the impact of Project Accelerate 2.0, the performance of breakout
opportunities, the integration and assumption of liabilities of businesses we
have acquired or may acquire in the future, fluctuations in foreign currency
exchange rates and their impact, our ability to successfully implement our
restructuring initiatives and other cost reduction initiatives, changing
technologies, product development and market demand and acceptance of our
products, the success of our R&D investment initiatives, the cost and pricing of
our products, risks that the anticipated benefits of the strategic partnership
with Biognosys or other commercial opportunities may otherwise not be fully
realized or may take longer to realize than expected; manufacturing,
competition, loss of key personnel, dependence on collaborative partners, key
suppliers and contract manufacturers, capital expenditures, debt levels, payment
of dividends, government funding policies, changes in governmental regulations,
the use and protection of intellectual property rights, litigation, and other
risk factors discussed from time to time in our filings with the
2 -Bruker Confidential-
--------------------------------------------------------------------------------
-Bruker Confidential-
--------------------------------------------------------------------------------
© Edgar Online, source